Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financi...(d in Montreal Canada and operates office...),Health

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the results of clinical trials, impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Complete financial statements for the quarter ended April 30, 2009 are available on Haemacure's web site, www.haemacure.com, and have been filed on Sedar.

    Financial Highlights
    (unaudited)
                                                      Quarters ended

                                              April 30, 2009  April 30, 2008
                                              --------------  --------------

    Sales                                            $18,765         $28,368
    General and administrative expenses             $631,681      $1,327,551
    Research and development expenses               $581,164        $668,452
    Total expenses                                $1,252,377      $2,520,807
    Net loss                                     $(1,242,150)    $(2,504,982)
    Loss per share                                    $(0.01)  
'/>"/>
SOURCE  HAEMACURE CORPORATION
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 
Related medicine news :

1. Haemacure and Angiotech Enter License, Distribution and Supply Agreements for Haemacures All-Human Fibrin Sealant and Thrombin Products
2. Haemacure Update on Proposed Collaboration and Bridge Financing
3. Haemacure Signs Term Sheet for Proposed Collaboration and Bridge Financing
4. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
5. Haemacure Restructures - Seeks Financing or Sale of the Company
6. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
7. Haemacure Announces Fiscal 2008 Results
8. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
9. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
10. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
11. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors